CILOA
Ciloa technology is the only one allowing to produce all types of membrane proteins with their native conformation on exosomes. It allows to load exosomes with cytosolic proteins as well. It thus makes it possible to reach the most difficult families of membrane protein targets, known as “undruggable”, some being the most promising for therapies.Ciloa takes advantage of the natural properties of exosomes; they are natural immuno-stimulators, biocompatible, intercellular membrane messengers, and able to cross all the human body barriers including the blood-brain barrier.
CILOA
Industry:
Legal Medical Therapeutics
Address:
Montpellier, Languedoc-Roussillon, France
Country:
France
Website Url:
http://www.ciloa.fr
Status:
Active
Contact:
+33 (0) 467 143 997
Email Addresses:
[email protected]
Total Funding:
5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics Font Awesome Apache
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Current Employees Featured
Official Site Inspections
http://www.ciloa.fr Semrush global rank: 5.83 M Semrush visits lastest month: 1.43 K
- Host name: cluster006.ovh.net
- IP address: 213.186.33.17
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Ciloa"
Ciloa, Inspired by exosomes
Ciloa is dedicated to the development of new high potential therapies. It was built on more than 15 years of research on bio-drug development technology using exosomes. Ciloa’s technology …See details»
EXPERIENCED MANAGEMENT TEAM - ciloa.fr
Robert founded Ciloa and was its CEO during 4 years. Expertise : viral RNA and proteins, virus isolation, epidemiology, phylogenesis, poly- & monoclonal antibodies, epitope mapping, 3D-modeling of proteins, diagnostics.See details»
Application fields - Ciloa
Ciloa's technology address several therapeutic areas through its three main applications : antibodies, vaccines, and therapeutic vectors. The antibodies and therapeutic vectors based …See details»
Ciloa | BIO-Europe Spring - Informa Connect
Ciloa is a French preclinical biotechnology company, spin-off from the CNRS and the University of Montpellier, with the world's leading experience in the development of exosome-based …See details»
Ciloa - Crunchbase Company Profile & Funding
View contacts for Ciloa to access new leads and connect with decision-makers. Ciloa technology is the only one allowing to produce all types of membrane proteins with their native conformation on exosomes. It allows to load …See details»
Ciloa SAS - LinkedIn
CILOA’S CUSTOMIZED EXOSOMES FOR INNOVATIVE THERAPEUTICS Ciloa is the most experienced exosome-based R&D Company dedicated to the development of new high …See details»
Ciloa - Eurobiomed
Ciloa agit sur la machinerie cellulaire impliquée dans la production d’exosomes et personnalise in vivo ces exosomes pour qu’ils contiennent i) des complexes protéiques membranaires natifs …See details»
Ciloa secures €5 million for the development of its new …
Montpellier, France, March 08th 2022 – Ciloa, a pioneer company expert in the in vivo customization of exosomes, announced today that it has secured €5 million to pursue its development programs for exosome-based biomedicines and …See details»
A BREAKTHROUGH EXOSOME TECHNOLOGY - Ciloa
Ciloa’s technology makes possible to have a cell producing a perfect antigen for an optimal immune response. We act directly on the cellular machinery to naturally produce membrane …See details»
Bio-Sourcing, Ciloa and Intract Pharma launch €3.4M …
May 28, 2024 · Ciloa is a French preclinical stage biotechnology company and pioneer in the field of extracellular vesicle bioengineering (EV). The company aims to create new generations of EV-based biotherapies and vaccines.See details»
Biotech, vaccins : Ciloa (Montpellier), une nouvelle unité de ...
Dec 8, 2020 · Dans le cadre du développement d’une nouvelle génération de vaccins et vecteurs thérapeutiques basée sur les exosomes, la biotech française Ciloa crée sa nouvelle unité de …See details»
Ciloa Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Ciloa. Use the PitchBook Platform to explore the full profile.See details»
Ciloa, les traitements thérapeutiques à base d’exosomes
Basée à Montpellier, la société développe une nouvelle génération de traitements fondés sur les exosomes, vésicules nanoscopiques qui transmettent des informations aux cellules du corps …See details»
Working with us - Ciloa
Ciloa is uniquely positioned to support your projects aiming to create new therapeutic and new preventive solutions. Our recombinant exosomes offer : Get unique answer to your needs with …See details»
Ciloa Secures €5 Million for the Development of Its New …
Mar 8, 2022 · MONTPELLIER, France-- ( BUSINESS WIRE )-- Ciloa, a pioneer company expert in the in vivo customization of exosomes, announced today that it has secured €5 million to …See details»
Montpellier : un aperçu de la médecine du futur à Ciloa, société ...
Feb 15, 2022 · La ministre de l’Enseignement supérieur, de la Recherche et de l’Innovation a en effet visité la société Ciloa, située au nord de la ville.See details»
Ciloa secures €5 million for biomedicines and vaccines development
Montpellier, France, March 08th 2022 – Ciloa, a pioneer company expert in the in vivo customization of exosomes, announced today that it has secured €5 million to pursue its …See details»
Ciloa veut utiliser les exosomes pour traiter des virus majeurs
Mar 7, 2022 · Société pionnière dans la personnalisation in vivo d'exosomes, qui sont de minuscules vésicules extracellulaires naturelles, Ciloa annonce ce lundi avoir réuni 5 millions …See details»
Contact - Ciloa
356 rue Maurice Bejart, Montpellier 34080, France. +33 (0) 499 745 987. [email protected]. CONTACT US. For information about the company, press relation, business development or …See details»